Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

American Journal of Cardiology

Volumn 90, Issue 9, 2002, Pages 947-952

  Freed, Martin I ^a,d   Ratner, Robert ^b   Marcovina, Santica M ^c   Kreider, Margaret M ^a   Biswas, Nandita ^a   Cohen, Beth R ^a   Brunzell, John D ^c  

^a GLAXOSMITHKLINE   (United States)

^b MEDSTAR RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSIGLITAZONE; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; DRUG TOLERABILITY; EDEMA; FEMALE; FLUID RETENTION; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG EVALUATION; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; NORTH AMERICA; PYRROLES; SAFETY; THIAZOLES; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036830104     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02659-0     Document Type: Article

References (30)

1. National Cholesterol Education Program (NCEP) Expert Panel . Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 285:2001;2486-2497.
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 20:1997;1183-1197.
3. Warnick G.R. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol. 129:1986;101-123.
4. Warnick G.R., Benderson J., Albers J.J. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem. 28:1982;1379-1388.
5. Warnick G.R. Measurement and clinical significance of high-density lipoprotein cholesterol subclasses. Rifai N., Warnick G.R., Laboratory Measurement of Lipids, Lipoproteins and Apolipoproteins. 1994;207-222 AACC Inc. Press, Washington, DC.
6. Marcovina S.M., Albers J.J., Henderson L.O., Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. III. Comparability of apolipoprotein A-I values by use of international reference material. Clin Chem. 39:1993;773-781.
7. Marcovina S.M., Albers J.J., Kennedy H., Mei J.V., Henderson L.O., Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem. 40:1994;586-592.
8. Zambon A., Hokanson J.E., Brown B.G., Brunzell J.D. Evidence for a new pathophysiological mechanism for coronary artery disease regression hepatic lipase-mediated changes in LDL density . Circulation. 99:1999;1959-1964.
9. Purnell J.Q., Kahn S.E., Albers J.J., Nevin D.N., Brunzell J.D., Schwartz R.S. Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab. 85:2000;977-982.
10. Howard B.V., Robbins D.C., Sievers M.L., Lee E.T., Rhoades D., Devereux R.B., Cowan L.D., Gray R.S., Welty T.K., Go O.T., Howard W.J. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL The Strong Heart Study . Arterioscler Thromb Vasc Biol. 20:2000;830-835.
11. Siegel R.D., Cupples A., Schaefer E.J., Wilson P.W. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism. 45:1996;1267-1272.
12. Packard C., Caslake M., Shepherd J. The role of small, dense low density lipoprotein (LDL) a new look . Int J Cardiol. 74:(suppl 1):2000;S17-22.
13. Lamarche B., Moorjani S., Lupien P.J., Cantin B., Bernard P.M., Dagenais G.R., Despres J.P. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation. 94:1996;273-278.
14. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 260:1988;1917-1921.
15. Nolan J.J., Jones N.P., Patwardhan R., Deacon L.F. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med. 17:2000;287-294.
16. Lebovitz H.E., Dole J.F., Patwardhan R., Rappaport E.B., Freed M.I. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 86:2001;280-288.
17. Phillips L.S., Grunberger G., Miller E., Patwardhan R., Rappaport E.B., Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 24:2001;308-315.
18. Tack C.J., Smits P., Demacker P.N., Stalenhoef A.F. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care. 21:1998;796-799.
19. Niemeijer-Kanters S.D., Dallinga-Thie G.M., de Ruijter-Heijstek F.C., Algra A., Erkelens D.W., Banga J.D., Jansen H. Effect of intensive lipid-lowering strategy on low-density lipoprotein particle size in patients with type 2 diabetes mellitus. Atherosclerosis. 156:2001;209-216.
20. Morikawa S., Umetani M., Nakagawa S., Yamazaki H., Suganami H., Inoue K., Kitahara M., Hamakubo T., Kodama T., Saito Y. Relative induction of mRNA for HMG CoA reductase and LDL receptors by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 7:2000;138-144.
21. Bakogianni M.C., Kalofoutis C.A., Skenderi K.I., Kalofoutis A.T. Clinical evaluation of plasma high-density lipoprotein subfractions (HDL2, HDL3) in non-insulin-dependent diabetics with coronary artery disease. J Diabetes Complications. 15:2001;265-269.
22. Lamarche B., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Despres J.P. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 17:1997;1098-1105.
23. Zambon A., Austin M.A., Brown B.G., Hokanson J.E., Brunzell J.D. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb. 13:1993;147-153.
24. Mowri H.O., Patsch J.R., Gotto A.M.J.r, Patsch W. Apolipoprotein A-II influences the substrate properties of human HDL2 and HDL3 for hepatic lipase. Arterioscler Thromb Vasc Biol. 16:1996;755-762.
25. Hime N.J., Barter P.J., Rye K.A. Evidence that apolipoprotein A-I facilitates hepatic lipase-mediated phospholipid hydrolysis in reconstituted HDL containing apolipoprotein A-II. Biochemistry. 40:2001;5496-5505.
26. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Torra I.P., Teissier E., Minnich A., Jaye M., Duverger N., et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 7:2001;53-58.
27. DiTusa L., Luzier A.B. Potential interaction between troglitazone and atorvastatin. J Clin Pharm Ther. 25:2000;279-282.
28. Harris R.Z., Inglis A.M., Miller A.K., Thompson K.A., Finnerty D., Patterson S., Jorkasky D.K., Freed M.I. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics. J Clin Pharmacol. 39:1999;1189-1194.
29. Inglis A.M., Miller A.K., Culkin K.T., Finnerty D., Patterson S.D., Jorkasky D.K., Freed M.I. Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. J Clin Pharmacol. 41:2001;683-690.
30. Baldwin S.J., Clarke S.E., Chenery R.J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol. 48:1999;424-432.